RPTECHNSERashi Peripherals LimitedLowNeutral
Announced Wed, 25 Mar · 19:46 IST

Rashi Peripherals Limited has informed the Exchange regarding Notice of Postal Ballot and E-Voting. The E-Voting period will remain open from Thursday, 26th March, 2026 09:00 AM (IST) till Friday, 24th April, 2026 05:00 PM (IST).

Board & Shareholder Meetings View source PDF

RPTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.9%1-day move
₹359.00
prior close
₹360.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.9+0.4-0.3-5.9-0.2+1.4+1.5+3.1+7.0+33.1+32.4+45.2+111.7
Up moveDown movePending
AI summary

Rashi Peripherals has issued a postal ballot notice for two special resolutions requiring shareholder approval through e-voting from March 26, 2026 to April 24, 2026. The first resolution seeks approval to formally appoint Mr. Rajesh Goenka as Whole-Time Director and CEO for a 5-year term (February 3, 2026 to February 2, 2031), with total remuneration of up to Rs. 14 crore per annum including salary, allowances, ESOPs, and retiral benefits; his FY 2025-26 pay is capped at Rs. 8 crore. The second resolution seeks approval to appoint Dr. Indumati Gopinathan (pathologist and current Independent Director at Thyrocare Technologies) as an Independent Director until the 38th AGM in 2027. Both candidates were initially appointed as Additional Directors on February 3, 2026, and now require shareholder ratification. The cut-off date for eligibility to vote is March 20, 2026.

Likely market impact

Routine governance actions seeking shareholder ratification of board appointments already effective from February 2026. The CEO's remuneration package (up to Rs. 14 crore/year including ESOPs) is notable and will be closely watched by shareholders as it requires special resolution approval. Approval of these resolutions is expected given they are board-recommended appointments; any rejection would create governance uncertainty and could impact management continuity.